CervoMed Inc.
CRVO · Price history
Price at last available close
$1.71
−$1.17 (-40.63%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About CervoMed Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
How they make money
CervoMed is a clinical-stage biotechnology company that does not currently generate commercial revenue from product sales. Its business model relies on funding research and development through equity financings, grants, and potential future out-licensing or commercialization of its lead product candidate, neflamapimod, for age-related neurologic disorders.
Products & services
The company's primary product candidate is neflamapimod, an oral small-molecule inhibitor of p38 MAP kinase, currently in clinical development for the treatment of dementia with Lewy bodies (DLB) and other neurodegenerative conditions.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Clinical trial participantsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct clinical trials and manage development activities.Source
- Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract manufacturers for the production of its clinical trial drug supplies.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
22
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
8
Poor
Financial Strength
0
Business Quality / Moat
0
Management
40
Growth Quality
0
Risk / Durability
2
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
Company-specific research
Questions worth answering for CRVO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can CRVO fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is CRVO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for CRVO to reach sustainable profitability?
- •What future growth or profitability would be needed to justify CRVO's current valuation?
- •What does the current none warning mean for the reliability or interpretation of CRVO's score?
Essential Investment Snapshot
Wall Street Score
22
Market Cap
$26.3M
P/E Ratio
-0.7
EPS
$-3.21
52-Week High
$10.00
52-Week Low
$2.13
Beta
-4.31
Analyst Target
$7.00
Shares Outstanding
9.0M
Total Revenue
$323K
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$2.54
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on CRVO.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Clinical development progress of neflamapimod.
- +Intellectual property portfolio in major international markets.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and lack of commercial revenue.
- −Dependence on clinical trial success and regulatory approval.
- −Need for additional capital to fund future operations.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
7 historical score records availablePrevious Score
23
Oct 1, 2026
Change
-0.7
points
Current Score
22
Oct 23, 2026
Category Changes
CRVO decreased 0.7 points because Asset declined by 5.9 points.
Negative Contributors
- − Asset declined by 5.9 points
Projected Score
Projected Score
21
Projected Change
-1.0 points
Preliminary comparable-period financial changes suggest decline of approximately 1.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.74
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $323K | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $323K | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $21.3M | $21.8M | $18.8M | $8.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $10.2M | $10.5M | $9.2M | $6.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $31.5M | $28.3M | $18.2M | $7.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$30.3M | -$27.0M | -$16.3M | -$2.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$31.2M | -$28.3M | -$18.2M | -$7.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$30.3M | -$27.0M | -$16.3M | -$2.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$30.3M | -$27.0M | -$16.3M | -$2.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-3.21 | $-2.98 | $-2.02 | $-0.82 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 10.24M | 9.04M | 8.07M | 2.66M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 10.24M | 9.04M | 8.07M | 2.66M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.64
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
+170.0%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
Potential Score Impact
Positive indicators included cash levels. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 8.6%. Cash increased 170.0%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
7 historical recordsHistorical Score Chart
3 of 7 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
CervoMed Shows Progress in Treating Rare Aphasia Condition
CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from HC Wainwright
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Brokerages
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Rumor Mill · CRVO
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial